Analysis of Immune Dysfunction and Predictors of Poor Prognosis in Patients with Alzheimer's Disease

Lei Liu
Guizhou Medical University

Hongmei Zeng
Guizhou Medical University

Qifang Zhang
Guizhou Medical University

Feifei Deng
Guizhou Medical University

Hua Bai (✉️ 842031616@qq.com)
Guizhou Medical University

Research

Keywords: Alzheimer's disease, Cellular immunity, Prognosis, T lymphocytes, Magnetic resonance spectroscopy

Posted Date: September 2nd, 2021

DOI: https://doi.org/10.21203/rs.3.rs-839108/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Analysis of immune dysfunction and predictors of poor prognosis in patients with Alzheimer's disease

Lei Liu¹,², Hongmei Zeng³, Qifang Zhang⁴,⁵, Feifei Deng¹, Hua Bai*¹,²,³

1. Department of Neurology, the Third Affiliated Hospital of Guizhou Medical University, Duyun 558099, China; 2. Department of Neurology, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China; 3. Medical Experimental Center of the Third Affiliated Hospital of Guizhou Medical University, Duyun 558099, China; 4. Key Laboratory of Endemic and Ethnic Diseases, Ministry of Education, Guizhou Medical University, Guiyang 550004, China; 5. Key Laboratory of Medical Molecular Biology, Guizhou Medical University, Guiyang 550004, China.

Corresponding author: Hua Bai, e-mail: baih2020@gmc.edu.cn

[Abstract] Background: Alzheimer's disease (AD) is a serious disease causing human dementia and social problems. The quality of life and prognosis of AD patients have attracted much attention. The role of chronic immune inflammation in the pathogenesis of AD is becoming more and more important. It is necessary to study the relationship among cognitive dysfunction, abnormal cellular immune function, neuroimaging results and poor prognostic factors in patients. Methods: A retrospective analysis of 62 hospitalized patients clinical diagnosed with AD who were admitted to our hospital from November 2015 to November 2020. Collect cognitive dysfunction performance characteristics, laboratory test data and neuroimaging data from medical records within 24 hours of admission, including MMSE score, drawing clock test (CTD), blood T lymphocyte subsets, and neutrophils and lymphocyte ratio (NLR), disturbance of consciousness, extrapyramidal symptoms, electroencephalogram (EEG) and head nucleus magnetic spectroscopy (MRS) and other data. Multivariate logistic regression analysis was used to determine independent prognostic factors. the modified Rankin scale (mRS) was used to determine whether the prognosis was good. The correlation between drug treatment and prognostic mRS score was tested by the rank sum test. Results: Univariate analysis showed that abnormal cellular immune function, extrapyramidal symptoms, obvious disturbance of consciousness, abnormal EEG, increased NLR, abnormal MRS, and complicated pneumonia were related to the poor prognosis of AD patients. Multivariate logistic regression analysis showed that the decrease in the proportion of T lymphocytes in the blood after abnormal cellular immune function [OR:2.078, 95%CI :1.156-3.986, P <0.05] was an independent risk factor for predicting the poor prognosis of AD. The number of days of donepezil treatment to improve cognitive function was negatively correlated with mRS score (r= 0.578, P <0.05). Conclusion: The decrease in the proportion of T lymphocytes may have predictive value for the poor prognosis of AD. It is recommended that the proportion of T lymphocytes <55% is used as the cut-off threshold for predicting the poor prognosis of AD. The early and continuous drug treatment is associated with a good prognosis.
1. Introduction

Alzheimer's disease (AD) is a neurodegenerative disease with severe cognitive dysfunction. The prominent clinical manifestations are memory loss, confusion of thinking and logic, and abnormal mental behavior. It accounts for about 40-60% of dementia patients (Scheltens et al., 2016; Jacus et al., 2020). At present, it is also inclined to think that AD is a chronic inflammatory disease mediated by abnormal autoimmune function. Mononuclear RNA sequencing and transcriptomics analysis show that the abnormal changes in microglia in the brain of AD patients induce a series of abnormal immune function. The activation of abnormal inflammasome represented by nucleotide-binding domain leucine-rich repeat and pyrin domain containing receptor protein 3 (NLRP3) inflammasome mediates the secretion of many immune inflammatory factors and subsequent cascades of chronic cascade reactions in immune inflammation (Lee et al., 2020; Yang et al., 2020). The amyloid β (Aβ) peptide produced by abnormal neurons precipitates and aggregates outside the cell. The hyperphosphorylation of tau protein can also easily cause aggregation, leading to neuron and nerve synaptic dysfunction and cell death, especially small glial cells. Reactive proliferation of glial cells often causes secondary cytopathological reactions in diseased brain regions (Ising et al., 2019). The activation of NLRP3 inflammasome promotes the aggregation of Aβ protein and the pathological formation of AD. The activation of NLRP3 inflammasome also contributes to the phosphorylation of tau protein and the accelerated development of AD. The interaction between Aβ and tau protein promotes the progression of AD. The onset and development of AD are usually mediated by abnormal immune function (Li et al., 2019; Olsen et al., 2016; Stancu et al., 2019).

At present, the diagnostic criteria of AD mostly depend on the screening of cognitive function scale and the exclusion of similar diseases. Although there are some biochemical markers of dementia in serum or cerebrospinal fluid, their specificity and sensitivity are not high (Egan et al., 2019; Cable et al., 2020). Combining some biochemical markers in blood or cerebrospinal fluid for early diagnosis of AD may be a direction of future efforts, among which some biochemical markers related to immunity have great research prospects. Some scholars have combined the detection results of magnetic resonance spectroscopy (MRS) with blood biochemical markers and achieved good results (Mielke et al., 2018). On the other hand, the research on the factors affecting the prognosis of AD also has important clinical and social significance. Some AD patients may have a long life, but whether this longevity has social value is worth exploring. Longevity with obvious lack of quality of life and heavy burden on families may
not be worth advocating. We need to make AD patients live a healthy life and return to society as much as possible (Reitz, 2015; Wang et al., 2020).

The role of chronic immune inflammation in the pathogenesis of AD is becoming more and more important. The ratio of neutrophil to lymphocyte (NLR) in blood is an important systemic inflammatory biomarker. NLR is calculated by absolute counting of neutrophils divided by absolute counts of lymphocytes. NLR has been reported to be increased in diabetes, hypertension, myocardial infarction, stroke and some tumor patients, which may be a new index to evaluate the prognosis of these patients (Kim et al., 2020; Sayed et al., 2020; Hamelin., 2018). The detection of T lymphocytes, B lymphocytes and natural killer cells in blood by flow cytometry can evaluate whether the immune function of AD patients is abnormal. Combined with the detection of relevant biochemical markers and EEG wave indexes by cranial MRS, it has great clinical significance for the early diagnosis and prognosis evaluation of AD patients. As far as we know, little research work has been carried out in this regard (Fani et al., 2021; Bregman et al., 2020). Therefore, this study focuses on the correlation between abnormal immune function and adverse prognostic factors in AD patients, and hope to find some valuable clues.

2. Method

2.1 Case study

This retrospective case study was reviewed and approved by the Medical Ethics Committee of the Third Affiliated Hospital of Guizhou Medical University in China. AD patients and their families hospitalized in the Department of Neurology and Psychiatry of the Third Affiliated Hospital of Guizhou Medical University were told to participate in the study and signed an informed consent form in accordance with the Declaration of Helsinki. The researchers checked the electronic medical records of 229 patients initially diagnosed with various types of dementia. These cases were patients who were discharged from the hospital between November 2015 and November 2020. The researchers re-evaluated the basis for the diagnosis of dementia in these cases, first confirmed or ruled out dementia through the Mini Mental State Examination Scale (MMSE) and the Cognitive Function Screening Scale, and then based on the medical history, clinical manifestations, and laboratory test results. In the diagnosis of AD, pay special attention to the use of the Harkinski Ischemic Scale (HIS) to identify AD. Excluded 14 patients with incomplete data and 7 patients lacking the basis for the diagnosis of dementia scales. The remaining 208 patients with various types of dementia were further differentiated, and 87 patients with vascular dementia (VD) and 53 patients with other non-AD dementia were excluded. AD is roughly equivalent to the dementia of phlegm obstruction in Chinese medicine. VD is roughly equivalent to the dementia of qi stagnation and blood stasis in Chinese Medicine.

The 68 patients in this retrospective study are all clinically diagnosed AD patients. The 68 AD patients who met the needs of this study were selected for follow-up. After the patients are
discharged from the hospital, they will be followed up and followed up by family members or guardians by telephone every 3 months. The prognosis will be assessed after detailed inquiries, and semi-quantitative according to the classic scale.

2.2 Data collection

Collect the following medical history and clinical data: age of onset, gender, chief complaint, duration of disease, first symptoms, other symptoms, main positive signs, cranial MRI, cranial magnetic spectroscopy (MRS), electroencephalogram (EEG), blood routine, blood immunity. Results of cell examination and drug treatment. The main metabolites detected by MRS include N-acetylaspartate (NAA), creatine (Cr), choline (Cho), inositol (MI), etc. NAA/Cr ratio and MI/Cr ratio were collected as key analysis indicators. Regarding EEG data, it is mainly to pay attention to the abnormal β wave and slow wave (θ wave and δ wave), especially the ratio of \((θ+δ)/(α+β)\) in the whole brain. We also pay attention to the ratio of neutrophils to lymphocytes (NLR) in the blood. The percentage values of T lymphocytes, B lymphocytes and natural killer cells (NK cells) detected by flow cytometry are also collected. As the value of Aβ protein and tau protein in the blood in the diagnosis of AD is controversial sometimes, this study was not collected. The decrease of Aβ42 protein in the cerebrospinal fluid (CSF) and the increase of phosphorylated tau protein do have certain value in the diagnosis of AD, but there are many lack of data in this group of cases, and they have not been collected. In addition, we collected MMSE score data and cognitive function screening scale scores for AD patients.

2.3 Prognosis assessment

The Modified Rankin Scale (mRS) was used to assess neurological function at admission, discharge, and follow-up. There are 6 grades of mRS score: 0 score is for full recovery; a score of 1 score is defined as having no apparent dysfunction or being able to perform daily life and work tasks despite symptoms; 2 score is mild disability, but basically able to complete daily life and work tasks independently; 3 score is moderate disability, unable to complete all previous activities, difficult to handle own affairs independently; 4 score is severely disabled and needs to be cared for by someone else; 5 score is severe disability who require intensive care by medical staff; 6 score is defined as death case. According to The mRS during the follow-up period, all patients were divided into two groups: Those with mRS score of 0-2 scores were defined as "good prognosis"; 3-6 scores was defined as "poor prognosis".
2.4 Statistical analysis

SPSS software was used for statistical analysis (version 17.0). The data collected are expressed as mean ± standard deviation or median (range). Count data is expressed as a ratio or percentage. Univariate correlation analysis was used to compare the differences between the two groups. Student t test or Mann Whitney test is used for measurement data, t test is used for variables with normal distribution, and Mann Whitney test is used for variables with non normal distribution. The counting data were compared by chi square test. Logistic regression analysis was used to determine the independent risk factors of poor prognosis. Differences in MRS scores between two groups were determined using Spearman rank correlation test. The best cut-off value of NAA/Cr as a prognostic index of AD was determined by the analysis of receptor working curve (ROC). P values less than 0.05 (bilateral) were considered statistically significant.

3. Results

3.1 Basic information of clinical data:

Through the electronic medical records database of the inpatient department and medical record room of the hospital, 229 cases of patients with clinical diagnosis of single or combined dementia were collected, including 87 cases of vascular dementia, 68 cases of Alzheimer's disease, and 53 cases of other dementia. These patients with other types of dementia included 3 cases of frontotemporal dementia, 2 cases of Lewy body dementia, 5 cases of Parkinson's disease dementia,
10 cases of chronic alcoholism dementia, 3 cases of dementia after carbon monoxide poisoning, 2 cases of dementia after AIDS infection, 3 cases of hypothyroid dementia, 2 cases of neurosyphilis paralytic dementia Cases, 4 cases of dementia after hydrocephalus, 1 case of dementia after heavy metal poisoning, 3 cases of dementia after organic pesticide poisoning, 6 cases of dementia after intracranial infection, 9 cases of mixed dementia. Another 7 patients did not meet the criteria for diagnosing dementia according to international standards, and the clinical data of 14 patients were incomplete. Of the 68 patients diagnosed with Alzheimer's disease, 6 patients had incomplete data or lost contact during the follow-up of this study (Figure 1 provides a schematic diagram of the process for selecting patients). The clinical diagnostic criteria of AD are verified in accordance with the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) of the American Psychiatric Association. Among the 62 patients with complete follow-up of AD, 7 had a family history of dementia, including 4 with APP gene mutation, 2 with PS-1 gene mutation, and 1 with PS-2 gene mutation.

Table 1. Clinical data and related characteristics of the AD patients

| Characteristics                        | patients |
|----------------------------------------|----------|
| Sex (male/female)                      | 24/38    |
| Age mean, range (years)                | 71, (55-92) |
| Interval between onset and hospitalization | 87, 5-547 |
| Mean, range (days)                     |          |
| Initial symptom                        |          |
| Hypomnesis                             | 19 (30.6%) |
| Apparent personality change           | 15 (24.2%) |
| Abnormal mental behavior               | 28 (45.1%) |
| Personality abnormality                | 34 (54.8%) |
| Recent memory deficits                 | 54 (87.1%) |
| Hallucination                          | 26 (41.9%) |
| Delusion of victimization              | 19 (30.6%) |
| Disturbance of consciousness           | 10 (16.1%) |
| Depressed                              | 20 (32.2%) |
| Abnormal EEG results                   | 48 (77.4%) |
| \((\theta+\delta)/(\alpha+\beta)\) more than 1.8 | 42 (67.7%) |
| Abnormal brain MRI results             | 52 (83.9%) |
| Encephalatrophy                        | 43 (69.4%) |
| Abnormality of hippocampus             | 36 (58.1%) |
| Ratio of NAA / Cr decreased            | 59 (95.2%) |
| NLR (median interquartile)             | 2.25 (1.59-2.97) |
| Proportion of T lymphocytes in blood   | 0.55 (0.47-0.63) |
| Proportion of B lymphocytes in blood   | 0.13 (0.09-0.18) |
| Proportion of NK cell in blood         | 0.11 (0.07-0.17) |

EEG: electroencephalogram; MRI: magnetic resonance imaging; NLR: neutrophil-to-lymphocyte ratio.
The 62 patients in this follow-up study were 55 to 92 years old (71±8.7 years old), 24 males and 38 females. All of them had chronic insidious onset and were sent to the hospital for treatment after they were found to have abnormal symptoms by their families. These patients had no history of major mental trauma, no history of head trauma, no history of drug abuse and toxicosis. The first symptoms were as follows: 19 cases (30.6%) of memory loss, 15 cases (24.2%) of personality changes, and 28 cases (45.1%) of abnormal mental behavior. The time from onset to hospital admission ranges from 5 days to 1.5 years. Initially, 35 patients (56.5%) were misdiagnosed as depression, schizophrenia, personality disorder, menopausal syndrome, affective psychological disorder and insomnia, etc. Throughout the course of the disease, all patients had obvious clinical manifestations of memory loss and abnormal mental behavior. The 54 patients had obvious short-term memory deficits, 34 patients had abnormal personality, 26 patients had hallucinations, 20 patients had significant depression, 19 patients had persecuted delusions, 12 patients had autonomic dysfunction, and 10 patients had varying degrees of consciousness disturbances, including special disturbances of consciousness, delirium and stupor. Follow-up was interrupted for 6 patients, two of whom died of complicated pneumonia and respiratory failure, one of whom died of complicated lung cancer metastasis and spread, one of whom died of complicated arrhythmia, and two of whom had family members who were unwilling to cooperate with follow-up. The clinical characteristics and other basic information of the AD patients studied were summarized (Table 1).

3.2 Auxiliary inspection results:

The data of Cranial MRI, MRS, EEG, blood routine, and blood immune cell tests were available for all patients. There were 52 cases with abnormal brain MRI, including 43 (69.4%) with brain atrophy, 22 (35.5%) with demyelinating lesions around the ventricle (white matter osteoporosis), and 36 (25.8%) with abnormal T2 signals in the hippocampus. There were 60 cases with abnormal brain Mrs, including 59 cases with decreased NAA / Cr (95.1%) and 56 cases with increased MI / Cr (90.3%). There were 48 cases (77.4%) with abnormal EEG examination, including 18 patients with high-amplitude β waves, 17 patients with more theta waves, 13 patients with δ waves, and the ratio of (θ+δ)/(α+β) is greater than 1.8 in 42 patients. Among the AD patients in this study, only 5 patients had mild abnormalities in routine blood tests, while the NLR value exceeded 4.5 in 20 patients and exceeded 4.0 in 46 patients. Blood immune cell examination found abnormal in 38 cases, mainly the proportion of T lymphocytes or NK cells decreased. The proportion of T lymphocytes was (55.4 ± 6.3)% in AD patients.

3.3 The relevant situation of the treatment effect:

All patients were treated with medications, mainly medications that may improve cognitive function. Among them, 48 patients were treated with Donepezil (5-10mg/d), 7 patients were treated with Niergoline, 5 patients were treated with Galantamine. Huperzine A was used in 2
cases. In addition, piracetam, oxiracetam, adenosine triphosphate, coenzyme Q10, vitamin E and other drugs were used for treatment. Risperidone, or Olanzapine, or Clozapine was used at the same time to control mental symptoms. All patients were not treated with transcranial magnetic therapy, acupuncture therapy, music therapy, psychotherapy and other treatment methods. The average follow-up time is 10 months (6-24 months). At the end of the follow-up, 16 patients (25.8%) had a good prognosis, 19 patients (30.6%) had a moderate prognosis, and 27 patients (43.6%) had a poor prognosis. mRS score: 5 points for 3 cases, 4 points for 7 cases, 3 points for 4 cases, 2 points for 17 cases, 1 point for 23 cases, 0 points for 8 cases. Among them, 28 cases were treated with risperidone alone to control their psychiatric symptoms, and the follow-up mRS score was 1-5 (3±0.72) points. Four patients died during the follow-up period, and 40 patients were hospitalized again during the follow-up period.

3.4 Prognosis and predictive factors

Univariate analysis showed that there were significant differences in five indexes in the corresponding auxiliary examination test values between the groups with good prognosis and poor prognosis, including Hallucination (P = 0.025), abnormal EEG (P = 0.003), the ratio of \((\theta+\delta)/(\alpha+\beta)\) by EEG (P=0.019), abnormality of hippocampus (P = 0.001), the proportion of T lymphocytes obtained by flow cytometry (P=0.008). We found that the proportion of T lymphocytes <55% can be used as the cut-off threshold for predicting the poor prognosis of AD. We also found that the ratio of \((\theta+\delta)/(\alpha+\beta)\) was usually greater than or equal to 1.8 in the poor prognosis group. In addition, patients with severe depressive symptoms, moderate or severe brain atrophy, severe abnormal electroencephalogram, and significantly reduced ratios of T lymphocytes or NK cells were associated with poor prognosis in AD patients (Table 2).
| Variables                                | Good prognosis (n=27) | Poor prognosis (n=35) | P value |
|------------------------------------------|-----------------------|-----------------------|---------|
| **Age (years), (mean ±SD)**              | 71.2 ± 15.3           | 70.6 ± 16.7           | 0.829   |
| **Sex**                                  |                       |                       |         |
| Male                                     | 11 (40.7%)            | 15 (42.9%)            | 0.867   |
| Female                                   | 16 (59.3%)            | 20 (57.1%)            |         |
| **Duration from onset to admission**     |                       |                       |         |
| < 90 days                                | 18 (66.7%)            | 22 (62.9%)            | 0.755   |
| ≥ 90 days                                | 9 (33.3%)             | 13 (37.1%)            |         |
| **Personality abnormality**              |                       |                       |         |
| Yes                                      | 15                    | 19                    | 0.092   |
| No                                       | 12                    | 16                    |         |
| **Recent memory deficits**               |                       |                       |         |
| Yes                                      | 22                    | 32                    | 0.247   |
| No                                       | 5                     | 3                     |         |
| **Hallucination**                        |                       |                       |         |
| Yes                                      | 7                     | 19                    | 0.025   |
| No                                       | 20                    | 16                    |         |
| **Delusion of victimization**            |                       |                       |         |
| Yes                                      | 5                     | 14                    | 0.069   |
| No                                       | 22                    | 21                    |         |
| **Disturbance of consciousness**        |                       |                       |         |
| Yes                                      | 2                     | 8                     | 0.101   |
| No                                       | 25                    | 27                    |         |
| **Depressed**                            |                       |                       |         |
| Yes                                      | 8                     | 12                    | 0.698   |
| No                                       | 19                    | 23                    |         |
| **Abnormal EEG results**                 |                       |                       |         |
| Yes                                      | 16                    | 32                    | 0.003   |
| No                                       | 11                    | 3                     |         |
| (θ+δ)/(α+β) from EEG                     |                       |                       |         |
| ≥ 1.8                                    | 14                    | 28                    | 0.019   |
| < 1.8                                    | 13                    | 7                     |         |
| **Abnormal brain MRI results**           |                       |                       |         |
| Yes                                      | 24                    | 28                    | 0.346   |
| No                                       | 3                     | 7                     |         |
| **Encephalatrophy**                      |                       |                       |         |
| Yes                                      | 20                    | 23                    | 0.479   |
| No                                       | 7                     | 12                    |         |
| **Abnormality of hippocampus**           |                       |                       |         |
| Yes                                      | 8                     | 28                    | 0.001   |
| No                                       | 19                    | 7                     |         |
| **NAA / Cr ratio decreased**             |                       |                       |         |
| Yes                                      | 25                    | 34                    | 0.408   |
| No                                       | 2                     | 1                     |         |
| **NLR (median IQR)**                     | 2.19 (1.51-2.87)      | 2.34 (1.62-3.28)      | 0.379   |
| Proportion of T lymphocytes in blood     | 0.63 (0.38-0.77)      | 0.37 (0.24-0.49)      | 0.008   |
| Proportion of B lymphocytes in blood     | 0.11 (0.08-0.18)      | 0.14 (0.10-0.23)      | 0.282   |
| Proportion of NK cell in blood           | 0.15 (0.08-0.19)      | 0.10 (0.06-0.16)      | 0.075   |

AD, Alzheimer’s disease; SD, standard deviation; IQR, interquartile range; EEG, electroencephalogram; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NLR, neutrophil-to-lymphocyte ratio; NAA; N-acetyl aspartate; Cr, creatine. P values <0.05 are considered statistically significant.
Table 3  Multivariate analysis of factors associated with a poor prognosis

| Variables                          | OR  | 95%CI      | P-value |
|------------------------------------|-----|------------|---------|
| Hallucination                      | 2.961| 0.265-18.397 | 0.723   |
| Abnormal EEG results               | 1.983| 0.079-7.531  | 0.682   |
| Abnormal brain MRI results         | 12.369| 0.592-39.127 | 0.849   |
| Abnormality of hippocampus         | 5.394| 0.275-78.364 | 0.231   |
| NAA/Cr ratio decreased             | 1.398| 0.056-135.284 | 0.816   |
| Proportion of T lymphocytes in blood | 3.265| 1.156-5.681  | **0.038** |

The NLR ratio in blood, the severity of memory impairment and the time of drug treatment had no significant correlation with the prognosis of AD patients. The ROC analysis of NAA / Cr obtained by MRS can predict the adverse prognosis of AD patients, and the area under the curve is 0.825 (95% CI, 0.126-0.958; P < 0.01). According to the ROC curve, the best intercept value is 1.52, the sensitivity is 85.6%, and the specificity is 89.3% (see Figure 2). Subsequently, Spearman correlation analysis or the Rank Sum test was performed. The correlation between the NAA/Cr ratio and mRS score after the treatment of donepezil in 28 patients was analyzed, and it was found that there was a positive correlation between the two group (r = 0.609, P < 0.05); The number of days of donepezil treatment to improve cognitive function was negatively correlated with mRS score (r= 0.578, P<0.05).

![ROC Curve](image)

**Figure 2.** ROC curve of the predictive value of NAA/Cr ratio of MRS for poor prognosis of AD.
4. Discussion

In this project, we retrospectively studied the subsequent prognosis of patients initially diagnosed with AD. We analyzed the clinical features, blood examination results, imaging data, EEG results and flow cytometry results. It also focused on the factors that are closely related to the poor prognosis. This study showed that the median T lymphocyte percentage in the poor prognosis group was significantly lower than that in the good prognosis group. The percentage of T lymphocytes in the blood to the total lymphocytes is an important indicator reflecting the cellular immune function. There have been studies by scholars supporting that reduced cellular immune function may promote the onset of AD (Bonotis et al., 2008), our research The results suggest that the reduced cellular immune function further makes the prognosis of AD patients worse. T lymphocytes are the main cells of cellular immunity. After being stimulated by antigens, T lymphocytes transform into sensitized T cells. They have direct killing effect on the invading antigen and the synergistic killing effect of cytokines released by sensitized T cells (Regen et al., 2017; Lodygin et al., 2019). In anti-infective immunity, cellular immunity is the main force of anti-infective immunity to participate in immune protection. In neurodegenerative diseases, the decrease of cellular immune function is more likely due to the reduction of the body's own immunity (Hur JY et al., 2020). After a transgenic AD mouse lacking T lymphocytes was cultured for 6 months, Marsh et al. (2016) found that the accumulation of beta amyloid in the brains of these mice was more than twice that of AD mice with intact immune systems. In addition, the neuroinflammation of Rag5xfad mice with immunodeficiency was significantly increased, which is manifested by changes in the phenotype of microglia, increased production of cytokines, and decreased phagocytic ability. It is speculated that the decline of cellular immune function is not only closely related to the onset of AD, but also has a greater relationship with the poor prognosis of AD.

MRS is an imaging technique that uses the principle of magnetic resonance and chemical shift phenomena to perform imaging and quantitative analysis of specific nuclei and related compounds (Chaney et al., 2019; Chandra et al., 2019). In the normal human brain, there are 5 resonance spectrum peaks in the MRS examination: NAA peak, Choline complex (Cho) peak, Cr peak, inositol peak, and glutamate peak. The decrease in NAA peak can be used as a sign of neuron loss or damage in the brain. The content of Cr in the gray matter of the brain is higher than that of the white matter, and it is a high energy phosphoric acid reserve substance for ATP/ADP conversion (Joe et al., 2019). This research found that the NAA/Cr ratio of the AD poor prognosis group was significantly lower than the NAA/Cr ratio of the good prognosis group. The decrease in NAA/Cr ratio indicates that there is more loss of bilateral hippocampal neurons, which can be
used as a biomarker for the transition from mild cognitive impairment to AD. Zhang et al. (Zhang et al., 2015) found that the NAA/Cr ratio of the posterior cingulate gyrus of MCI patients who progressed to AD dementia was lower than that of patients who progressed to Lewy body dementia (DLB). The prognosis of AD type dementia and DLB. Kantarci et al. (Kantarci et al., 2004) tested the cranial MRS of AD, VD, and DLB patients and found that NAA/Cr in AD and VD patients were lower than normal. AD patients had NAA/Cr lower than DLB patients. The Cho/Cr ratio of AD and DLB patients was higher than normal. The researcher believe that in dementia characterized by neuronal loss, NAA/Cr ratio is reduced, and in dementia characterized by severe cholinergic insufficiency, Cho/Cr ratio is elevated. By examining the cranial MRS of AD patients, it can not only be used to diagnose AD, but also be used to evaluate the prognosis of AD patients.

EEG examination is mainly used for differential diagnosis of epilepsy, as well as auxiliary diagnosis of encephalitis and certain encephalopathy (Bagattini et al., 2019). This study also found that the prognosis of AD patients with a ratio of $(\theta+\delta)/(\alpha+\beta)$ greater than or equal to 1.8 obtained by EEG was poor, suggesting that careful EEG analysis also has a certain value in judging the prognosis of AD. Engedal et al. (2020) used statistical pattern recognition (SPR) quantitative electroencephalography (qEEG) to predict the conversion rate of dementia in patients with subjective cognitive decline (SCD) and MCI, and conducted follow-up. Of the 200 participants with complete data, 70 cases progressed from other conditions to dementia, and 52 cases developed to AD. Based on the EEG test results, the receiver operating characteristics analysis showed that the area under the curve was 0.78, the corresponding sensitivity was 71%, and the specificity was 69%. Researcher believe these SCD and MCI patients are at high risk of developing dementia within five years. Our study also found that the clinical prognosis of AD patients with severe depressive symptoms, moderate or severe brain atrophy, and severe abnormal EEG is poor. These aspects need to be grasped as a whole and further analyzed. Olichney et al. (Olichney et al., 2008) believed that when abnormal N400 and P600 repeat effects were detected by cognitive event related potential (ERP) in AD patients, it indicated that the synaptic plasticity in the brain of the patients had been significantly abnormal. Abnormalities of P600 or N400 in MCI patients are significantly associated with an increased risk of subsequent conversion to AD, and ERP test could provide a useful biomarker for the diagnosis of AD patients.

NLR is considered to be an easy to detect and operate systemic inflammatory index, which is related to the abnormal cellular immune function. Based on the above considerations, we analyzed the impact of NLR on the prognosis of AD patients. The results showed that there was no significant correlation between the ratio of NLR in blood and the prognosis of AD patients.
Rembach et al. (2014) found that the sensitivity of NLR itself is not enough to diagnose AD. There is indeed a certain correlation between NLR and neocortical amyloid load in the cross section, but this relationship disappeared after longitudinal analysis. Moreover, the association between NLR and cognitive decline is also limited. They believe that NLR may only reflect the peripheral blood related inflammatory process, which is greatly affected by age and gender. These research results and views are basic consistent with our conclusion. Under normal circumstances, a small number of activated T cells enter the brain and participate in immune monitoring, but the infiltration of a large number of T cells usually occurs in the case of severe chronic immune inflammation in AD. Macrophages rather than microglia are the main phagocytes in the brain. These infiltrating cells are the key to the repair process. Giving anti-inflammatory treatment at the appropriate time of the disease can reduce the risk of Aβ pathological damage caused by deposition (Laurent et al., 2018; Long et al., 2019; Lee et al., 2018).

However, our research had some limitations. First, this study was a retrospective analysis, and it is difficult to control confounding factors. Second, the items related to the detection of cellular immune function were incomplete, and lymphocyte transformation test and immunoglobulin test were not carried out. Third, the sample size of this study is relatively small, and it is a single institution study, and the popularization value of the conclusion is limited. Nevertheless, this research still has some valuable findings in predicting the correlation between abnormal cellular immune function and poor prognosis in AD patients.

5. Conclusion

The decrease in the proportion of T lymphocytes may have predictive value for the poor prognosis of AD. It is suggested that the proportion of T lymphocytes less than 55% should be used as the cut-off threshold for predicting the poor prognosis of AD. In addition, MRS combined with EEG detection is also worthy of recognition in predicting the poor prognosis of AD. Yet the early and continuous drug treatment that improve cognitive function is associated with a good prognosis.

**Abbreviations:** Aβ, amyloid β; AD, Alzheimer’s disease; Cho, choline; Cr, creatine; CSF, cerebrospinal fluid; CTD, drawing clock test; EEG, electroencephalogram; ERP, event related potential; HIS, Harkinski Ischemic Scale; IQR, interquartile range; MI, inositol; MRI, magnetic resonance imaging; mRS, modified Rankin scale; MRS, magnetic spectroscopy; NAA, N-acetylaspartate; NLR, neutrophils and lymphocyte ratio; NLRP3, nucleotide-binding domain leucine-rich repeat and pyrin domain containing receptor protein 3; SD, standard deviation.

**Ethics approval and consent to participate:** This study was approved by the Institutional Ethical Committee of the Third Affiliated Hospital of Guizhou Medical University in China on October 12, 2015 (approval No.2015-19-1). The authors certify that they have obtained the consent forms
from participants. In the form, participants have given their consent for their clinical information to be reported in the journal. The participants understand that their names will not be published.

**Consent to publish:** The publish and copyright license agreement has been signed by all authors before publication.

**Availability of data and materials:** Datasets analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interests:** The authors declare that they have no conflict of interest.

**Funding:** This work was supported by National Natural Science Foundation of China (to BH), No:32060182, and the grant of Science and Technology Support Plan of Guizhou Province in China, No: QianKeHe-Zhicheng [2020]4Y129 (to BH).

**Authors' Contributions:** Study design, fundraising and manuscript preparation: BH; investigation and data collection: LL, ZHM, DFF; results analysis and discussion: LL, ZQF, BH. All authors approved the final version of this manuscript.

**Trial registration:** No applicable.

**Acknowledgements:** Thanks nurses and doctors from Department of Neurology, Department of Psychiatry, The Third Affiliated Hospital of Guizhou Medical University in China for their cooperation and help in the telephone follow-up to cases.

**References**

[1] Bagattini C, Mutanen TP, Fracassi C, Manenti R, Cotelli M, Ilmoniemi RJ, Miniussi C, Bortolotto M (2019) Predicting Alzheimer's disease severity by means of TMS-EEG coregistration. Neurobiol Aging 80:38-45.

[2] Bonotis K, Krikki E, Holeva V, Aggouridaki C, Costa V, Baloyannis S (2008) Systemic immune aberrations in Alzheimer's disease patients. J Neuroimmunol 193:183-187

[3] Bregman N, Kavé G, Zeltzer E, Biran I (2020) Memory impairment and Alzheimer's disease pathology in individuals with MCI who underestimate or overestimate their decline. Int J Geriatr Psychiatry 35:581-588

[4] Cable J, Holtzman DM, Hyman BT, Tansey MG, Colonna M, Kellis M, Brinton RD, Albert M, Wellington CL, Sisodia SS, Tanzi RE (2020) Alternatives to amyloid for Alzheimer's disease therapies a symposium report. Ann N Y Acad Sci 1475:3-14.

[5] Chaney A, Williams SR, Boutin H (2019) In vivo molecular imaging of neuroinflammation in Alzheimer's disease. J Neurochem 149:438-451.

[6] Chandra A, Dervenoulas G, Politis M (2019) Alzheimer's Disease Neuroimaging Initiative. Magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment. J Neurol 266:1293-1302.

[7] Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M, Zhang Y, Li W, et al. (2019) Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. N Engl J Med 380:1408-1420.

[8] Engedal K, Barca ML, Hogh P, Bo Andersen B, Winther Dombrowsky N, Naik M,
[9] Fani L, Georgakis MK, Ikram MA, Ikram MK, Malik R, Dichgans M (2021) Circulating biomarkers of immunity and inflammation, risk of Alzheimer's disease, and hippocampal volume: a Mendelian randomization study. Transl Psychiatry 1 : 291.

[10] Hamelin L, Lagarde J, Dorothée G, Potier MC, Corlier F, Kuhnast B, Caillé F, Dubois B, Fillon L, Chupin M, Bottlaender M, Sarazin M (2018) Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease. Brain 141:1855-1870.

[11] Hur JY, Frost GR, Wu X, Crump C, Pan SJ, Wong E, Barros M, Li T, Nie P, Zhai Y, Wang JC, Tcw J, Guo L, et al (2020) The innate immunity protein IFITM3 modulates gamma-secretase in Alzheimer's disease. Nature 586 : 735-740.

[12] Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, Schwartz S, Albasset S, McManus RM, Tejera D, Grieb A, Santarelli F, et al (2019) NLRP3 inflammasome activation drives tau pathology. Nature 575 : 669-673.

[13] Jacus JP, Mayelle A, Voltzenlogel V, Cuervo-Lombard CV, Antoine P (2020) J Alzheimers Dis. Modelling Awareness in Alzheimer's Disease 76 : 89-95

[14] Joe E, Medina LD, Ringman JM, O'Neill J (2019) (1)H MRS spectroscopy in preclinical autosomal dominant Alzheimer disease. Brain Imaging Behav 13 : 925-932.

[15] Kantarci K, Petersen RC, Boeve BF, Knopman DS, Tang-Wai DF, O'Brien PC, Weigand SD, Edland SD, Smith GE, Ivnik RJ, Ferman TJ, Tangalos EG, Jack CR Jr (2004) 1H MR spectroscopy in common dementias. Neurology 63 : 1393-1398.

[16] Kim MS, Kim Y, Choi H, Kim W, Park S, Lee D, Kim DK, Kim HJ, Choi H, Hyun DW, Lee JY, Choi EY, Lee DS, Bae JW, Mook-Jung I (2020) Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer's disease animal model. Gut 69 : 283-294.

[17] Laurent C, Buée L, Blum D (2018) Tau and neuroinflammation: what impact for Alzheimer's disease and tauopathies? Biomed J 41 : 21-33.

[18] Lee JY, Han SH, Park MH, Baek B, Song IS, Choi MK, Takuwa Y, Ryu H, Kim SH, He X, Schuchman EH, Bae JS, Jin HK (2018) Neuronal SphK1 acetylates COX2 and contributes to pathogenesis in a model of Alzheimer's Disease. Nat Commun 9 : 1479.

[19] Lee JY, Jin HK, Bae JS (2020) Sphingolipids in neuroinflammation: a potential target for diagnosis and therapy. BMB Rep 53 : 28-34.

[20] Li L, Ismael S, Nasoohi S, Sakata K, Liao FF, McDonald MP, Ishrat T (2019) Thioredoxin-Interacting Protein Associated NLRP3 Inflammasome Activation in Human Alzheimer's Disease Brain. J Alzheimers Dis 68 : 255-265.

[21] Lodygin D, Hermann M, Schweingruber N, Flügel-Koch C, Watanabe T, Schlosser C, Merlini A, Körner H, Chang HF, Fischer HJ, Reichardt HM, Zagrebelsky M, Mollenhauer B, Kügler S, Fitzer D, Frahm J, Stadelmann C, Haberl M, Odoardi F, Flügel A (2019). beta-Synuclein-reactive T cells induce autoimmune CNS grey matter degeneration. Nature 566 : 503-508.

[22] Long H, Zhong G, Wang C, Zhang J, Zhang Y, Luo J, Shi S (2019) TREM2 Attenuates
Aβ1-42-Mediated Neuroinflammation in BV-2 Cells by Downregulating TLR Signaling. Neurochem Res 44: 1830-1839.

[23] Marsh SE, Abud EM, Lakatos A, Karimzadeh A, Yeung ST, Davtyan H, Fote GM, Lau L, Weinger JG, Lane TE, Inlay MA, Poon WW, Blurton-Jones M (2016) The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function. Proc Natl Acad Sci USA 113: E1316 -E1325

[24] Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, Airey DC, Knopman DS, Roberts RO, Machulda MM, Jack CR Jr, Petersen RC, Dage JL (2018) Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement 14: 989-997

[25] Olichney JM, Taylor JR, Gatherwright J, Salmon DP, Bressler AJ, Kutas M, Iragui-Madoz VJ (2008) Patients with MCI and N400 or P600 abnormalities are at very high risk for conversion to dementia. Neurology 70: 1763-7170

[26] Olsen I, Singhrao SK (2016) Inflammasome Involvement in Alzheimer's Disease. J Alzheimers Dis. 54: 45-53.

[27] Regen F, Hellmann-Regen J, Costantini E, Reale M (2017) Neuroinflammation and Alzheimer's Disease: Implications for Microglial Activation. Curr Alzheimer Res 14: 1140-1148.

[28] Reitz C (2015). Genetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunities. Expert Rev Mol Diagn 15: 339-348.

[29] Rembach A, Watt AD, Wilson WJ, Rainey-Smith S, Ellis KA, Rowe CC, Villemagne VL, Macaulay SL, Bush AI, Martins RN, Ames D, Masters CL, Doecke JD (2014) An increased neutrophil-lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation. J Neuroimmunol 273: 65-71.

[30] Sayed A, Bahbah EI, Kamel S, Barreto GE, Ashraf GM, Elfil M (2020) The neutrophil-to-lymphocyte ratio in Alzheimer's disease: Current understanding and potential applications. J Neuroimmunol 349: 577398.

[31] Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM (2016) Alzheimer's disease. Lancet 388: 505-517.

[32] Stancu IC, Cremers N, Vanrussett H, Couturier J, Vanoosthuyse A, Kessels S, Lodder C, Bröne B, Huaux F, Octave JN, Terwel D, Dewachter I (2019) Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo. Acta Neuropathol 137: 599-617.

[33] Wang M, Peng IF, Li S, Hu X (2020) Dysregulation of antimicrobial peptide expression distinguishes Alzheimer's disease from normal aging. Aging (Albany NY) 12: 690-706.

[34] Yang J, Wise L, Fukuchi K (2020) TLR4 Cross-Talk With NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease. Front Immunol 11: 724.

[35] Zhang B, Ferman TJ, Boeve BF, Smith GE, Maroney-Smith M, Spychalla AJ, Knopman DS, Jack CR Jr, Petersen RC, Kantarci K (2015) MRS in mild cognitive impairment: early differentiation of dementia with Lewy bodies and Alzheimer's disease. J Neuroimaging 25: 269-274.
Table Legends:

Table 1. Clinical data and related characteristics of the AD patients.
EEG: electroencephalogram; MRI: magnetic resonance imaging; NLR: neutrophil-to-lymphocyte ratio.

Table 2  Univariate analysis of prognostic factors associated with AD.
AD, Alzheimer’s disease; SD, standard deviation; IQR, interquartile range; EEG, electroencephalogram; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NLR, neutrophil-to-lymphocyte ratio; NAA; N-acetyl aspartate; Cr, creatine. P values <0.05 are considered statistically significant.

Table 3  Multivariate analysis of factors associated with a poor prognosis

Figure Legends:

Figure 1. Flowchart of the study.

Figure 2. ROC curve of the predictive value of NAA/Cr ratio of MRS for poor prognosis of AD.
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- GraphicalAbstract.pdf